ICP
XLRN

Interchange Capital Partners’s Acceleron Pharma XLRN Stock Holding History

Interchange Capital Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-201
Closed -$25K – 1218
2020
Q4 		$25K Buy
+201
New +$23.6K 0.01% 569

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Interchange Capital Partners's XLRN Position: Q1 2021 in Review

Interchange Capital Partners sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 201 shares — an estimated $25K sold.

Interchange Capital Partners first reported a position in XLRN in Q4 2020 and held it in 1 quarter. The position peaked at $25K in Q4 2020. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

  • Interchange Capital Partners reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 201 Acceleron Pharma shares in Q1 2021, an estimated $25K.
  • Interchange Capital Partners first reported a position in Acceleron Pharma in Q4 2020 and held it in 1 quarter.
  • Interchange Capital Partners's Acceleron Pharma position peaked at $25K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.